深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》， 具体情况如下： 二、对公司的影响 硫酸脱氢表雄酮（DHEA-S）是最丰富的肾上腺雄激素，也是一种由肾上腺 皮质产生的神经类固醇。作为肾上腺雄激素分泌的良好指标，DHEA-S 仅表现出 较弱的雄激素活性，但可以代谢为更活跃的雄激素，如睾酮和雄烯二酮。血清和 血浆 DHEA-S 的水平高于所有其他类固醇。男性和女性的 DHEA-S 水平在 30 岁 左右达到最高水平，之后随着年龄的增长而下降。DHEA-S 的半衰期较长，约为 8-10 小时，远长于半衰期约为 30-60 分钟的其他雄激素，且 DHEA-S 日变化有限， 是一种简便的评价肾上腺分泌激素的指标。 截至本公告披露日，公司及控股子公司已取得 108 个电化学发光配套检测试 剂注册证。上述产品注册证的获得，进一步丰富和完善 ...

Core Viewpoint - The company has received a medical device registration certificate for its DHEA-S testing kit, enhancing its competitive position in the immunodiagnostics market [1] Group 1: Product Development - The company has obtained the "Medical Device Registration Certificate" from the Guangdong Provincial Drug Administration for the DHEA-S testing kit, which is used for the quantitative measurement of DHEA-S levels in human serum or plasma [1] - The DHEA-S testing kit is clinically used to evaluate the level of androgen secretion from the adrenal glands, indicating its relevance in medical diagnostics [1] Group 2: Market Impact - The acquisition of the registration certificate enriches the company's portfolio of electrochemiluminescence reagent projects, potentially improving its market competitiveness in the immunodiagnostics field [1] - The actual sales performance of the product post-launch will depend on future marketing efforts, and the specific impact on the company's future performance remains unpredictable [1]

Group 1 - The core business of the company includes in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health, and it does not involve brain engineering [2]

Core Viewpoint - The company has established a comprehensive incentive mechanism, utilizing a variety of methods to motivate core personnel and attract more talented individuals, with the stock option incentive plan being one of the diverse incentive methods [1] Summary by Relevant Sections - Stock Option Plans - The exercise price for the stock option incentive plan established in 2021 was set at 21.00 yuan per share, while the 2022 plan's exercise price was set at 20.00 yuan per share, both of which are higher than the company's current stock price [1] - The stock option incentive plans are based on a self-exercise model, allowing the incentive recipients to decide on exercising options based on the exercise price, stock price, and their own financial situation [1] - Incentive Mechanism - The company has developed a well-rounded incentive mechanism that includes various incentive methods to motivate key personnel and attract more outstanding talent [1]

Core Viewpoint - The company, Pumen Technology (688389.SH), clarified that its main business does not include the brain engineering sector, focusing instead on in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health [2] Summary by Relevant Categories Business Scope - The company's primary operations encompass in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health [2] Investor Interaction - An investor inquired whether the company's medical device business falls under the brain engineering sector, to which the company responded that it currently does not engage in this area [2]

Group 1 - Ugreen Technology expects a net profit of 653 million to 733 million yuan for 2025, representing a year-on-year growth of 41.26% to 58.56% [1] - SenTai Co. plans to invest no more than 140 million yuan to establish a production base in Vietnam [2] - Muyuan Foods reported a December 2025 sales revenue of 9.667 billion yuan from commodity pigs, a year-on-year decline of 36.06% [3] Group 2 - Pumen Technology has received a medical device registration certificate for a quality control product used in various cancer markers [4] - Heng Rui Medicine's subsidiary has received approval for clinical trials of two injection drugs targeting obesity [5] - Quartz Co. was fined 2.7 million yuan for commercial secret infringement by its subsidiary [6] Group 3 - Chifeng Gold expects a net profit of 3 billion to 3.2 billion yuan for 2025, an increase of approximately 70% to 81% year-on-year [7] - Fulong Technology has terminated the transfer of 82.0969 million shares [8] - Senba Sensor's actual controller has released the pledge of 16.48 million shares [9] Group 4 - Hanma Technology reported a cumulative truck sales increase of 58.45% for 2025 [12] - Guankang Clean won a bid for a special procurement project worth 157 million yuan [14] - Defu Technology signed a cooperation agreement for high-end copper foil supply with a leading CCL company [15] Group 5 - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology [16] - CanSino received approval for clinical trials of a 24-valent pneumococcal polysaccharide conjugate vaccine [17] - Yipin Hong's subsidiary received approval for a supplementary application for oseltamivir phosphate capsules [19] Group 6 - Taotao Vehicle expects a net profit of 800 million to 850 million yuan for 2025, a year-on-year increase of 85.50% to 97.10% [20] - Yutong Bus reported a cumulative sales increase of 5.54% for 2025 [21] - Kingoo Co. received a notification from VinFast to supply automotive wheel products [22] Group 7 - ST Renfu's subsidiary received approval for clinical trials of a new drug for late-stage solid tumors [23] - Nanxing Co. expects a net profit of 90 million to 120 million yuan for 2025, reversing a loss from the previous year [24] - Jinrui Mining's subsidiaries will undergo routine maintenance starting January 5, 2026 [25] Group 8 - Changjiang Power reported a 3.82% increase in total power generation for its six hydropower stations in 2025 [26] - David Medical's subsidiary received a medical device registration certificate for an electronic endoscope image processor [28] - Guiguan Power reported a 26.68% increase in cumulative power generation for 2025 [29] Group 9 - ShenNan Electric's subsidiary won a project worth 208 million USD for a power plant operation service [30] - ST Kaiyuan's major shareholder's shares will be auctioned [31] - Jiecheng Co.'s major shareholder's shares have been auctioned [32] Group 10 - Tongbao Energy's wind power project has begun generating electricity [33] - Xusheng Group received an order worth 7.8 billion yuan from a North American EV manufacturer [34] - Qianli Technology reported a 154.08% increase in December 2025 electric vehicle production [35] Group 11 - Chint Electric plans to issue H-shares and list on the Hong Kong Stock Exchange [36][37] - Whirlpool expects a net profit increase of approximately 150% for 2025 [38] - Yongjie New Materials signed a 2 billion yuan aluminum alloy procurement contract [39]

Core Viewpoint - The company has received a medical device registration certificate from the National Medical Products Administration for its tumor marker quality control product, enhancing its competitive position in the in vitro diagnostic market [1] Group 1: Product Registration - The product, named tumor marker quality control product, is classified as Class III and has a registration number valid until December 28, 2030 [1] - This product is designed for quality control in conjunction with various detection kits for prostate-specific antigens and other cancer markers [1] Group 2: Market Impact - The acquisition of this registration certificate enriches the company's product offerings in the in vitro diagnostic field, potentially improving its market competitiveness in immunodiagnostics [1] - The actual sales performance of the product post-launch will depend on future market promotion efforts, and the specific impact on the company's future performance remains uncertain [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●本次行权数量： 1、深圳普门科技股份有限公司（以下简称"公司"）2021年股票期权激励 计划（以下简称"2021年激励计划"）首次授予股票期权第三个行权期可行权数 量为4,198,000份，行权有效期为2024年11月8日至2025年10月10日。2025年10月1 日至2025年12月31日期间，累计行权并完成股份过户登记数量为0股。 证券代码：688389 证券简称：普门科技 公告编号：2026-001 深圳普门科技股份有限公司 关于股票期权激励计划2025年第四季度 自主行权结果的公告 2、公司2022年股票期权激励计划（以下简称"2022年激励计划"）首次授 予股票期权第三个行权期可行权数量为3,164,800份，行权有效期为2025年6月30 日至2026年5月8日。2025年10月1日至2025年12月31日期间，累计行权并完成股 份过户登记数量为0股。 ●本次行权股票上市流通时间： 公司股票期权激励计划均采用自主行权模式行权，激励对象行权所得股 ...

证券代码：688389 证券简称：普门科技 公告编号：2026-002 本次取得注册证的产品为复合质控品，以样本测量程序测定质控品，将测定 结果进行统计分析或与参考值（参考范围）比较，判断结果是否满足要求，以此 确保公司电化学发光检测系统的安全、有效。 截至本公告披露日，公司及控股子公司已取得 107 个电化学发光配套检测试 剂注册证。上述产品注册证的获得，进一步丰富和完善了公司在体外诊断领域的 产品品种，有利于进一步提升公司在免疫诊断领域的市场竞争力，对公司未来的 经营将产生积极影响。 1 / 2 产品名称 注册 分类 注册证 编号 注册证 有效期至 预期用途 肿瘤标志物 质控品 III 类 国械注准 20253402676 2030 年 12 月 28 日 本质控品与本公司试剂盒配合使用，用于 总前列腺特异性抗原（tPSA）、游离前列 腺特异性抗原（fPSA）、甲胎蛋白（AFP）、 铁蛋白（Ferritin）项目检测时的质量控制； 与重庆普门创生物技术有限公司试剂盒 配合使用，用于癌抗原 125（CA125）、 癌抗原 15-3（CA15-3）、糖类抗原 19-9 （CA19-9）、癌抗原 72-4（CA ...

（记者 曾健辉） 每经AI快讯，普门科技1月5日晚间发布公告称，深圳普门科技股份有限公司于近期收到了1个国家药品 监督管理局颁发的《中华人民共和国医疗器械注册证》。产品名称为"肿瘤标志物质控品"。 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 ...